ARMO BioSciences, Inc. Common Stock
ARMO
ARMO was delisted on the 21st of June, 2018.
65 hedge funds and large institutions have $509M invested in ARMO BioSciences, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 65 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$173M |
| 2 |
AI
Alphabet Inc
Mountain View,
California
|
+$51.1M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$50.8M |
| 4 |
BlackRock
New York
|
+$34.6M |
| 5 |
HH
HSG Holding
Na,
Hong Kong
|
+$34M |
Top Sellers
ARMO Hedge Fund Activity: Q1 2018 in Review
65 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in ARMO BioSciences, Inc. Common Stock (ARMO) for Q1 2018, worth a combined $509M.
Buyers outnumbered sellers: 65 funds opened new ARMO positions and 0 closed out — a net gain of 65 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $173M.
- 65 institutional investors held ARMO BioSciences, Inc. Common Stock (ARMO) as of Q1 2018, up from 0 in Q4 2017.
- Funds reported $509M of ARMO BioSciences, Inc. Common Stock stock for Q1 2018.
- 65 funds opened new ARMO BioSciences, Inc. Common Stock positions in Q1 2018 and 0 closed out, a net change of +65 holders.
- The largest ARMO BioSciences, Inc. Common Stock buyer in Q1 2018 was OrbiMed, an estimated $173M added.
Based on aggregated 13F filings for Q1 2018.